• German pharmaceutical research and development remains stagnant despite government efforts to strengthen the sector, according to the October 20, 2026, PROUD update.
• Life sciences equity investment fell 15%, highlighting financing gaps that risk driving drug development projects, intellectual property and expertise abroad.
• Industry-sponsored Phase I trials declined 10%; gene and cell therapy trials dropped 39%, widening the gap between research and commercial development.
• Germany’s share of global clinical trial patient recruitment stagnated at about 3%, despite continued strength in basic medical research.
• Experts’ rating of Germany’s overall attractiveness fell to 5.65 from 5.80 out of 10, marking a second consecutive annual decline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioM Biotech Cluster Development GmbH published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.